Tempus AI, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TEM research report →
Companywww.tempus.com
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
- CEO
- Eric Lefkofsky
- IPO
- 2024
- Employees
- 2,400
- HQ
- Chicago, IL, US
Price Chart
Valuation
- Market Cap
- $7.91B
- P/E
- -26.77
- P/S
- 5.80
- P/B
- 19.48
- EV/EBITDA
- -41.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 69.55%
- Op Margin
- -18.13%
- Net Margin
- -22.20%
- ROE
- -70.24%
- ROIC
- -13.27%
Growth & Income
- Revenue
- $1.27B · 83.41%
- Net Income
- $-245,028,000 · 65.28%
- EPS
- $-1.41 · 69.35%
- Op Income
- $-238,635,000
- FCF YoY
- -13.25%
Performance & Tape
- 52W High
- $104.32
- 52W Low
- $41.73
- 50D MA
- $49.46
- 200D MA
- $66.46
- Beta
- 3.99
- Avg Volume
- 5.61M
Get TickerSpark's AI analysis on TEM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Fukushima Ryan | other | 162,239 |
| May 14, 26 | Fukushima Ryan | other | 62,239 |
| May 4, 26 | Schoenherr Thomas Edward | other | 13,642 |
| May 4, 26 | Rogers James William | other | 10,000 |
| May 4, 26 | Polovin Andrew | other | 10,000 |
| May 4, 26 | Bartolucci Ryan M | other | 24,000 |
| May 4, 26 | Fukushima Ryan | other | 10,000 |
| Apr 28, 26 | LEFKOFSKY ERIC P | sell | 105,430 |
| Apr 28, 26 | LEFKOFSKY ERIC P | sell | 27,570 |
| Apr 28, 26 | LEFKOFSKY ERIC P | sell | 26,360 |
Our TEM Coverage
We haven't published any research on TEM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TEM Report →